GeoVax Vaccine to Enter Phase IIa Human Trials
February 26, 2008
GeoVax Labs has said that its HIV/AIDS vaccine is one of the select few to move forward into Phase IIa human trials by the HIV Vaccine Trials Network or HVTN, a network supported by the National Institutes of Health.
According to the company, this newly planned Phase II trial is tentatively scheduled to start mid-2008 and will involve up to 500 participants at several locations in the US.
Harriet Robinson, senior vice president, R&D at GeoVax, said: “Our vaccine continues to demonstrate the promise of not only being safe but also effective at eliciting potentially protective immune responses.”